Tyrosine 308 is Necessary for Ligand-directed Gs Protein-biased Signaling of β2-adrenoceptor
Overview
Authors
Affiliations
Interaction of a given G protein-coupled receptor to multiple different G proteins is a widespread phenomenon. For instance, β2-adrenoceptor (β2-AR) couples dually to Gs and Gi proteins. Previous studies have shown that cAMP-dependent protein kinase (PKA)-mediated phosphorylation of β2-AR causes a switch in receptor coupling from Gs to Gi. More recent studies have demonstrated that phosphorylation of β2-AR by G protein-coupled receptor kinases, particularly GRK2, markedly enhances the Gi coupling. We have previously shown that although most β2-AR agonists cause both Gs and Gi activation, (R,R')-fenoterol preferentially activates β2-AR-Gs signaling. However, the structural basis for this functional selectivity remains elusive. Here, using docking simulation and site-directed mutagenesis, we defined Tyr-308 as the key amino acid residue on β2-AR essential for Gs-biased signaling. Following stimulation with a β2-AR-Gs-biased agonist (R,R')-4'-aminofenoterol, the Gi disruptor pertussis toxin produced no effects on the receptor-mediated ERK phosphorylation in HEK293 cells nor on the contractile response in cardiomyocytes expressing the wild-type β2-AR. Interestingly, Y308F substitution on β2-AR enabled (R,R')-4'-aminofenoterol to activate Gi and to produce these responses in a pertussis toxin-sensitive manner without altering β2-AR phosphorylation by PKA or G protein-coupled receptor kinases. These results indicate that, in addition to the phosphorylation status, the intrinsic structural feature of β2-AR plays a crucial role in the receptor coupling selectivity to G proteins. We conclude that specific interactions between the ligand and the Tyr-308 residue of β2-AR stabilize receptor conformations favoring the receptor-Gs protein coupling and subsequently result in Gs-biased agonism.
Molecular Modeling Study of a Receptor-Orthosteric Ligand-Allosteric Modulator Signaling Complex.
Jiang C, He X, Wang Y, Chen C, Othman Y, Hao Y ACS Chem Neurosci. 2023; 14(3):418-434.
PMID: 36692197 PMC: 10032570. DOI: 10.1021/acschemneuro.2c00554.
Tian X, Zhang J, Wang S, Gao H, Sun Y, Liu X Front Pharmacol. 2022; 13:919325.
PMID: 36120357 PMC: 9478952. DOI: 10.3389/fphar.2022.919325.
Ligands of Adrenergic Receptors: A Structural Point of View.
Wu Y, Zeng L, Zhao S Biomolecules. 2021; 11(7).
PMID: 34202543 PMC: 8301793. DOI: 10.3390/biom11070936.
Jozwiak K, Plazinska A Molecules. 2021; 26(4).
PMID: 33561962 PMC: 7915493. DOI: 10.3390/molecules26040851.
Receptor-Arrestin Interactions: The GPCR Perspective.
Seyedabadi M, Gharghabi M, Gurevich E, Gurevich V Biomolecules. 2021; 11(2).
PMID: 33557162 PMC: 7913897. DOI: 10.3390/biom11020218.